Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Osimertinib As First-Line Treatment of <i>EGFR</i> Mutation–Positive Advanced Non–Small-Cell Lung Cancer

PaperCitations, authors & open-access status

Osimertinib As First-Line Treatment of <i>EGFR</i> Mutation–Positive Advanced Non–Small-Cell Lung Cancer is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 544 citations, 2017 year and closed oa status.

544
Citations
2017
Year
closed
OA Status

Related on ScholarIQ

Kenneth S. Thress
Author
James Chih‐Hsin Yang
Author
Dong‐Wan Kim
Author
Pasi A. Jänne
Author
Journal of Clinical Oncology
Journal
Lung Cancer Treatments and Mutations
Topic
470M+ articles · free account